Zura Bio Limited
NASDAQ:ZURABiotechnology
+$0.07 today
- Market cap
- $92.96M
- Beta
- 0.03
- P/E (TTM)
- -5.5
- EPS (TTM)
- -$0.67
Volume 3.02M
Average 0.75M
ZURA Account Payables
Amounts the company owes suppliers for goods and services received.
Zura Bio LimitedNASDAQ: ZURA
Account Payables · Q1 FY2026 · quarter ended Mar 2026
Account payables rises 66.8% from a year ago
Account payables stood at $2.08M at the end of Q1 FY2026, up 66.8% from a year earlier and up 62.9% from the prior quarter. Over 3 fiscal years it compounded at -14.0% a year.
Context
- Account payables amounted to 0.9% of total assets at the end of Q1 FY2026, up 0.2 pp from a year earlier.
- Account payables increased in 2 of the last 3 fiscal years.
What to watch
Whether account payables keeps rising in the next quarterly balance sheet after a +66.8% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Account Payables history
USD · from the balance sheet
- Latest · FY2025
- 1.28M USD
- Year-over-year change
- +74.5%
| Period | Period end | Account Payables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.28M | +74.5% |
| FY2024 | 2024-12-31 | 733K | -73.3% |
| FY2023 | 2023-12-31 | 2.75M | +36.8% |
| FY2022 | 2022-12-31 | 2.01M | — |
| FY2021 | 2022-03-31 | 0 | — |
Account Payables vs competitors
How ZURA compares with its peers on the latest reported figures
- ZURA's Mar 2026 account payables of $2.08M is the 8th highest of the 11 companies compared; the peer median is $3.71M.
- Its year-over-year change of +66.8% is the 4th highest of 11, against a peer median of +10.4%.
- Account payables amounts to 0.9% of total assets for ZURA, versus a peer median of 1.5%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $1.45B | +110780.3% | -21.2% | 0.7% | |
| Mar 2026 | $4.99M | +75.3% | +15.3% | 7.8% | |
| Mar 2026 | $4.49M | +75.8% | +100.0% | 4.6% | |
| Mar 2026 | $4.36M | -8.3% | -31.3% | 1.4% | |
| Mar 2026 | $4.09M | -33.8% | -17.2% | 1.7% | |
| Mar 2026 | $3.32M | -18.5% | -7.6% | 1.5% | |
SGMTSagimet Biosciences Inc. | Mar 2026 | $2.3M | -28.5% | +5.2% | 2.1% |
ZURAZura Bio Limited | Mar 2026 | $2.08M | +66.8% | -14.0% | 0.9% |
| Mar 2026 | $1.91M | -62.2% | -28.0% | 1.4% | |
| Mar 2026 | $1.19M | +41.0% | -9.5% | 0.7% | |
| Mar 2026 | $1.13M | +29.0% | -22.3% | 0.5% | |
| Peer median (excluding ZURA) | $3.71M | +10.4% | -13.3% | 1.5% | |
Competitors are the stored peer set for ZURA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Zura Bio Limited
NASDAQ:ZURA
Intrinsic Alpha fair value
Locked
Current Price
$0.97
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.